ANAVEX 2-73 blarcamesine
Selected indexed studies
- Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial. (J Prev Alzheimers Dis, 2025) [PMID:39800452]
- ANAVEX®2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome. (Pharmacol Biochem Behav, 2019) [PMID:31704481]
_Worker-drafted node — pending editorial review._